Metastatic Adrenocortical Carcinoma: a Single Institutional Experience

Area of Science:

• Oncology
• Endocrinology
• Cancer Research

Background:

• Adrenocortical carcinoma (ACC) is a rare cancer with limited data on managing metastatic disease.
• Optimal treatment strategies and outcomes for metastatic ACC are critical areas of research.

Purpose of the Study:

• To retrospectively analyze clinical characteristics and outcomes of patients with metastatic ACC.
• To evaluate the prognostic impact of clinical factors and the role of liver-directed therapies.

Main Methods:

• Retrospective review of 65 ACC patients treated between 1997-2016.
• Survival analysis using Kaplan-Meier and Cox regression models.
• Focus on 36 patients receiving systemic therapy for metastatic disease.

Main Results:

• Median overall survival from diagnosis was 27 months; from systemic treatment, 18.7 months.
• Bone, lung, liver metastases, ascites, and hormonal activity were not prognostic.
• Six patients with liver metastases receiving liver-directed therapy (TACE/SIRT) showed improved survival (p=0.011).

Conclusions:

• This study provides insights into ACC clinical characteristics and outcomes.
• Liver-directed therapies may offer a survival benefit for ACC patients with hepatic metastases.